Jagsonpal Pharmaceuticals Reports Q2 Results and Strategic Acquisitions
Jagsonpal Pharmaceuticals Ltd · Outcome · 28 Oct 2026, 11:43 pm
Jagsonpal Pharmaceuticals Reports Q2 Results and Strategic Acquisitions Jagsonpal Pharmaceuticals reported standalone Q2 revenue from operations of ₹813.75m, up 9.28% YoY from ₹744.65m, with net profit rising slightly to ₹125.90m from ₹125.74m. For H1 ended 30th Sep'26, standalone revenue stood at ₹1,636.07m with net profit at ₹257.79m. Consolidated Q2 revenue reached ₹963.71m and net profit was ₹122.87m, reflecting the consolidation of newly acquired 85% stake in Aequitas Healthcare for ₹208m effective 1st Jul'26. Additionally, the company signed a BTA on 23rd Sep'26 to acquire Group Pharmaceuticals' Wellness Portfolio.
Original exchange filing (PDF)
More announcements from Jagsonpal Pharmaceuticals Ltd
- Earning call transcript for Jagsonpal Pharmaceuticals Limited Q2 FY 27 Earning Conference Call on October 29, 2026 at 2:00 P.M · 03 Nov 2026
- Audio Recording of Jagsonpal Pharmaceuticals Limited Q2 FY27 Earnings Conference call on October 29, 2026 at 02:00 P.M. · 29 Oct 2026
- Press Release for Unaudited Financial Results for the quarter September 30, 2026 · 29 Oct 2026
- Press Release for Unaudited Financial Results for the quarter ended September 30, 2026. · 29 Oct 2026
- Unaudited Financial Results (Standalone & Consolidated for the quarter and half year ended September 30, 2026. · 28 Oct 2026
- Outcome of Board Meeting held on October 28, 2026 along with Unaudited Financial Results(Standalone & Consolidated) for the quarter and half year ended September 30, 2026 · 28 Oct 2026
- JAGSONPAL PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 28-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . · 28 Oct 2026
- Intimation of Analysts/Investors Conference Call · 29 Oct 2026
